Searching:
Search by keyword, patent number, inventor, assignee, city or state:
| Patent # | Description |
|---|---|
| US-7,988,998 |
Sustained-release tramadol formulations with 24-hour efficacy A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2... |
| US-7,988,997 |
Rapidly-decomposing administrable form for releasing active ingredients in
the oral cavity or in bodily cavities A dosage form which is, in particular, sheet-like and rapidly disintegrating or soluble in an aqueous environment for rapid release of active ingredients in the... |
| US-7,988,996 |
Pharmaceutical tablets with height greater than width Described is a compressed multiple layer pharmaceutical tablet that has a height that exceeds the width of the tablet. The height is measured vertically from... |
| US-7,988,995 |
Pharmaceutical compositions for lipophilic drugs Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic... |
| US-7,988,994 |
Capsule formulation of pirfenidone and pharmaceutically acceptable
excipients A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of... |
| US-7,988,993 |
Oral controlled release dosage form A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate... |
| US-7,988,992 |
Superporous hydrogels for heavy-duty applications The present invention features modified superporous hydrogels (SPHs) and methods for their formation. The SPHs of the present invention are prepared by careful... |
| US-7,988,991 |
Adhesive patch A patch agent of the present invention comprises a support, and an adhesive layer laid on the support and containing an adhesive base and a drug, wherein the... |
| US-7,988,990 |
Thin aqueous cataplasm A thin aqueous cataplasm prepared by laminating an adhesive layer (base) having specified constituents on a support which consists of a fiber film prepared by... |
| US-7,988,989 |
Nutritional product for enhancing growth and/or strengthening the immune
system of equine foals A novel nutritional product and methods for the manufacture and administration of the same are disclosed for the feeding of equine foals and other animals. The... |
| US-7,988,988 |
Contact lenses with mucin affinity A biomedical device, such as a contact lens, has a surface linked to a polymer comprising boronic acid moieties. The boronic acid monomeric units may be derived... |
| US-7,988,987 |
Medical devices containing crazed polymeric release regions for drug
delivery A medical device that contains (a) at least one polymeric release region that either contains crazing or which is adapted to undergo crazing as a result of... |
| US-7,988,986 |
Implant filling material and method Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous... |
| US-7,988,985 |
Pest repellent compositions and methods The invention is directed to a topical insect repellent with extended duration of protection and that was obtained by combining natural and organic plant... |
| US-7,988,984 |
Insect repellent and attractant and auto-thermostatic membrane vapor
control delivery system A membrane enclosed fluid diffusion system for insect attractants and repellents, auto thermostatic heaters, and chemical delivery using an additive and/or... |
| US-7,988,983 |
Microencapsulation coating for gloves The present invention provides for a coating having microcapsules for use with a glove. The coating improves both wet and dry and donnability of the glove. The... |
| US-7,988,982 |
Cosmetic composition with anti-free radical activity A cosmetic composition has an association of at least three of the following substances with anti-free radical activity, selected from: 1) ebselen; or... |
| US-7,988,981 |
Multiphase cosmetic composition The present invention relates to a multi-phase cosmetic composition for application to the body, which has a liquid and transparent appearance, becomes a... |
| US-7,988,980 |
Tuberculosis vaccine with improved efficacy The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel... |
| US-7,988,979 |
Neisseria meningitidis antigens and compositions The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are... |
| US-7,988,978 |
Composition and method for controlling intestinal pathogenic organisms An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes seven field... |
| US-7,988,977 |
Modified live Aeromonas hydrophila vaccine for aquatic animals Safe and effective live vaccines against Aeromonas hydrophila of fish were created through the induction of rifampicin resistance in native Aeromonas hydrophila... |
| US-7,988,976 |
Method for enhancing antioxidant component of Gracilaria tenuistipitata
extract A method for enhancing antioxidant components of Gracilaria tenuistipitata extract is proposed. The method involves providing an extraction environment of... |
| US-7,988,975 |
Modified HIV-1 group M cyclic gp41 peptides and their use in the detection
of anti-HIV-1 antibodies The invention involves a synthetic peptide derived from HIV-1 virus gp41 having sequence ##STR00001## where X.sub.615 is F or G, a method of preparing the... |
| US-7,988,974 |
Antifusogenic proteins comprising human immunodeficiency virus type 1
(HIV-1) gp41 DP-178 polypeptide variants... The present invention relates to fusion peptides which exhibit potent anti-retroviral activity. The fusion peptides of the invention comprise a macromolecular... |
| US-7,988,973 |
Activin-ActRII antagonists and uses for increasing red blood cell levels In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including... |
| US-7,988,972 |
Immunoreactive peptides from Epstein-Barr virus The Epstein-Barr virus (EBV) specific polypeptides ETFTETWNRFITHTE (SEQ. ID NO: 1), GMLEASEGLDGWIHQ (SEQ. ID NO:2), HQQGGWSTLIEDNIP (SEQ. ID NO:3), and... |
| US-7,988,971 |
Human monoclonal antibodies against Hendra and Nipah viruses The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such... |
| US-7,988,970 |
Methods of treatment comprising administering an anti-sclerostin antibody Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing... |
| US-7,988,969 |
Treatment for central nervous system disorders Compositions that include an A.beta. polypeptide linked to a non-A.beta. polypeptide are described, as well as methods of using such compositions. |
| US-7,988,968 |
Method of treating an IL-1 related coronary condition An IL-1.beta. binding antibody or IL-1.beta. binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors,... |
| US-7,988,967 |
High affinity human antibodies to human nerve growth factor A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with K.sub.D of 5 pM or less, as measured... |
| US-7,988,966 |
Method for the potentiation of opioid analgesics effects on pain According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one... |
| US-7,988,965 |
Methods of treating systemic lupus erythematosus with an antibody against
costimulatory signal transduction... Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen... |
| US-7,988,964 |
NOGO-a neutralising immunoglobulin for treatment of neurological diseases The present invention provides immunoglobulins, particularly antibodies that bind to NOGO and neutralise the activity thereof, polynucleotides encoding such... |
| US-7,988,963 |
Use of allogeneic cell lines to load antigen presenting cells to elicit or
eliminate immune responses Novel antigen-presenting cells, including but not limited to dendritic cells, that are loaded with antigens from dead or dying cells including allogenic cell... |
| US-7,988,962 |
Use of polysulphated alginate in cellular matrices The present invention describes an in vitro/ex vivo method for the cultivation of connective tissue cells or progenitor cells (e.g. chondrogenic cells) in... |
| US-7,988,961 |
Gut commensal bacterium and methods of using the same The invention provides gut commensal bacteria that have been modified to express one or more biologically active polypeptides or protiens, the bacteria includes... |
| US-7,988,960 |
Probiotics in primary prevention of atopic diseases The present invention is in the field of prophylaxis of allergies, and relates specifically to primary prevention of atopic diseases by administering probiotic... |
| US-7,988,959 |
Method of treatment using organotypically cultured skin tissue comprising
niks cells that express exogenous HIF-1a The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth... |
| US-7,988,958 |
Enterococcus and Streptococcus strains and bacteriocins Novel Enterococcus and Streptococcus bacteriocins produced by novel Enterococcus and Streptococcus strains are used for at least reducing the levels of... |
| US-7,988,957 |
Gene introduction efficiency enhancer A gene transfer efficiency enhancer of the present invention which contains a histone deacetylase inhibitor (especially compound (A)) as an active ingredient is... |
| US-7,988,956 |
Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) Poly(ethylene glycol) carbamate derivatives useful as water-soluble pro-drugs are disclosed. These degradable poly(ethylene glycol) carbamate derivatives also... |
| US-7,988,955 |
Conditioning composition The present invention is related to stabilization of color of conditioning compositions for hair on aqueous basis, suitable for use after using cleansing... |
| US-7,988,954 |
Hair treatment composition comprising sugar lactone An aqueous hair treatment composition comprising: a) from 0.01% to 10% by weight of the total composition of beeswax; and b) from 0.01% to 10% by weight of the... |
| US-7,988,953 |
UV absorbing chromophores covalently bonded to hyperbranched polymers The invention provides a conjugate comprising a hyperbranched polymer covalently bonded to at least three UV absorbing chromophores having an UV absorption... |
| US-7,988,952 |
Delivery of drug esters through an inhalation route The present invention relates to the delivery of drug esters through an inhalation route. Specifically, it relates to aerosols containing drug esters that are... |
| US-7,988,951 |
Method for inducing selectively suppressed immune response to transplanted
tissue or cells Transimmunization methods incorporating skin immunologic challenges are described for either selectively suppressing the immune response of recipients of... |
| US-7,988,950 |
Contrast agents endowed with high relaxivity for use in magnetic resonance
imaging (MRI) which contain a... The present invention relates to a novel class of paramagnetic ion-based contrast i agents of formula (I), wherein a chelating backbone moiety is highly... |
| US-7,988,949 |
Nanoparticles for protein drug delivery The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one antibiotics or equivalent bioactive agent characterized... |
Copyright 2008−2013 Patents.com
